Markets

Revvity Rolls Out GSP T1D 3plex Kit

Sep 24, 2026 · 08:03 AM ET· updated 1h ago

Revvity, Inc. (NYSE: RVTY) today announced the launch of the GSP® T1D 3plex kit, a fully automated, CE-IVDR-certified, multiplex autoantibody (AAb) detection solution to enable population-wide screening programs that

Why It Matters

Revvity launched a new tool that screens for type 1 diabetes in large groups. When companies release new products that work well, it can show business growing.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

RVTY146.91

+4.80 (+3.38%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.